160 related articles for article (PubMed ID: 31640596)
21. Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy.
Chusri P; Kumthip K; Pantip C; Thongsawat S; O'Brien A; Maneekarn N
Virus Res; 2015 Jan; 196():37-43. PubMed ID: 25445343
[TBL] [Abstract][Full Text] [Related]
22. Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.
Seko Y; Akuta N; Suzuki F; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Intervirology; 2013; 56(1):13-21. PubMed ID: 22907167
[TBL] [Abstract][Full Text] [Related]
23. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.
European Association of the Study of the Liver
Liver Int; 2012 Feb; 32 Suppl 1():2-8. PubMed ID: 22212565
[TBL] [Abstract][Full Text] [Related]
24. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
Nordstrom EM; Keniston A; Baouchi F; Martinez-Camacho A
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117
[TBL] [Abstract][Full Text] [Related]
25. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
Zeuzem S; Lee JH; Roth WK
Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
[TBL] [Abstract][Full Text] [Related]
26. How to optimize current treatment of genotype 2 hepatitis C virus infection.
Marciano S; Gadano AC
Liver Int; 2014 Feb; 34 Suppl 1():13-7. PubMed ID: 24373073
[TBL] [Abstract][Full Text] [Related]
27. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
28. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
[TBL] [Abstract][Full Text] [Related]
29. Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong.
Hui YT; Wong GLH; Fung JYY; Chan HLY; Leung NWY; Liu SD; Liu K; Ma YK; But DYK; Mak WY; Chan JMC; Lai KB; Loo CK; Ng ACY; Lai MS; Chan CW; Lau JYL; Fan TTT; Hui AJ; Lam BCY; Cheung WI; Tsang OTY; Lam K; Lai LSW; Luk WF; Li MKK; Lao WC; Lam JTW; Tsang SWC; Kung KN; Chow WH; Tong RKN; Lui TKL; Shan EHS; Yuen MF; Wong VWS
Liver Int; 2018 Nov; 38(11):1911-1919. PubMed ID: 29981176
[TBL] [Abstract][Full Text] [Related]
30. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.
Kurosaki M; Enomoto N; Murakami T; Sakuma I; Asahina Y; Yamamoto C; Ikeda T; Tozuka S; Izumi N; Marumo F; Sato C
Hepatology; 1997 Mar; 25(3):750-3. PubMed ID: 9049230
[TBL] [Abstract][Full Text] [Related]
31. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.
Yu ML; Lee CM; Chen CL; Chuang WL; Lu SN; Liu CH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Su WW; Lin CL; Yang HC; Chen PJ; Chen DS; Liu CJ;
Hepatology; 2013 Jun; 57(6):2135-42. PubMed ID: 23322699
[TBL] [Abstract][Full Text] [Related]
32. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence is not a predictive factor for response to interferon-alpha therapy and development of hepatocellular carcinoma.
Bae SH; Park YM; Yoo DG; Choi JY; Byun BH; Yang JM; Lee CD; Cha SB; Park DH; Kim BS
J Korean Med Sci; 2000 Feb; 15(1):53-8. PubMed ID: 10719809
[TBL] [Abstract][Full Text] [Related]
33. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
Selvapatt N; Habibi MS; Brown A
J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
[TBL] [Abstract][Full Text] [Related]
34. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.
Welzel TM; Bhardwaj N; Hedskog C; Chodavarapu K; Camus G; McNally J; Brainard D; Miller MD; Mo H; Svarovskaia E; Jacobson I; Zeuzem S; Agarwal K
J Hepatol; 2017 Aug; 67(2):224-236. PubMed ID: 28343981
[TBL] [Abstract][Full Text] [Related]
35. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy.
Serpaggi J; Chaix ML; Batisse D; Dupont C; Vallet-Pichard A; Fontaine H; Viard JP; Piketty C; Rouveix E; Rouzioux C; Weiss L; Pol S
AIDS; 2006 Jan; 20(2):233-40. PubMed ID: 16511416
[TBL] [Abstract][Full Text] [Related]
36. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
37. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
Cardoso AC; Moucari R; Figueiredo-Mendes C; Ripault MP; Giuily N; Castelnau C; Boyer N; Asselah T; Martinot-Peignoux M; Maylin S; Carvalho-Filho RJ; Valla D; Bedossa P; Marcellin P
J Hepatol; 2010 May; 52(5):652-7. PubMed ID: 20346533
[TBL] [Abstract][Full Text] [Related]
38. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
[TBL] [Abstract][Full Text] [Related]
39. [Diagnosis and treatment of chronic hepatitis C. Practical recommendations and new developments].
Niederau C
Med Klin (Munich); 2001 Oct; 96(10):599-607. PubMed ID: 11715332
[TBL] [Abstract][Full Text] [Related]
40. Influence of viral genotype and level of viremia on the severity of liver injury and the response to interferon therapy in Spanish patients with chronic C infection.
Fernández I; Castellano G; Domingo MJ; Fuertes A; Colina F; Canga F; de la Cruz FJ; de la Cámara AG; Solís JA
Scand J Gastroenterol; 1997 Jan; 32(1):70-6. PubMed ID: 9018770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
